Bionik Laboratories Corp. · OTC:BNKL
Bionik Laboratories — Investor Presentation (May 2016)
27 slides from Bionik Laboratories's investor presentation, May 5, 2016
Slide 1: Corporate Presentation May 2016
www.bioniklabs.com OTCQX:BNKL Pioneering global medical device and robotics company focused on providing rehabilitation solutions to individuals with neurological disorders Corporate Presentation May 2016
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward - looking statements relating to future events or the future financial performance and operations of Bionik . Forward - looking statements, which involve assumptions and describe Bionik’s intent, belief or current expectations about its business op
Slide 3: Bionik Investment Highlights
Bionik Investment Highlights • Pipeline of commercial and development stage robotic products addressing both upper and lower body rehabilitation • Recent acquisition of Interactive Motion Technologies adds 3 commercial stage products characterized as Class II medical devices by the U.S. FDA and sold
Slide 4: Recent Acquisition Expected to Position Bionik as a Leading Robotics and Medical Device Company
Recent Acquisition Expected to Position Bionik as a Leading Robotics and Medical Device Company 4 • Robotics company developing solutions for individuals with neurological disorders • Primary program ARKE • Global pioneer in robotic rehabilitation therapy for central nervous system disorders • Multi
Slide 5: Emergence of Rehabilitation Robotics
Emergence of Rehabilitation Robotics • 2014: Rehabilitation robots market at $43.3 million* • 2020: Rehabilitation robots market expected to grow to $1.8 billion* • Includes exoskeletons and active prosthetics • Growth is a result of effectiveness of robotic treatment* • Rehabilitation robots being
Slide 6: Product Portfolio Addressing Upper and Lower Body
Product Portfolio Addressing Upper and Lower Body 6 Product Optimization Pre - clinical Clinical Approval InMotion Arm™ InMotion Hand™ InMotion Wrist™ ARKE™ InMotion Ankle™ Lower Body Robot Internal R&D
Slide 7: Upper Extremity Commercial-Stage Product Line
Upper Extremity Commercial - Stage Product Line • InMotion ARM • Designed to rehabilitate stroke patients with upper body neurological limitations • Evidence based, intelligent, interactive technology capable of continuously adapting to and challenging the patient's ability • Allows the clinician to
Slide 8: Lower Body Development-Stage Product Pipeline
Lower Body Development - Stage Product Pipeline • InMotion ANKLE™ • Exoskeletal robotic system using the same design principles in upper extremity rehabilitation • Designed in close collaboration with the Newman Laboratory for Biomechanics and Human Rehabilitation at MIT • Currently available in mul
Slide 9: ARKE
ARKE A robotic lower body exoskeleton designed to allow paraplegics as well as other wheelchair users, the ability to rehabilitate through walking TM
Slide 10: ARKE: Product Details
ARKE: Product Details • Sensors throughout the device sense body movement and trigger motion • Constructed with carbon fiber, aluminum and steel • Fully customizable to fit patients of all heights and weights • Connects to Bionik’s cloud software where data is analyzed and displayed back to the phys
Slide 11: Collaboration with IBM
Collaboration with IBM 11 Data is collected from ARKE and analyzed utilizing IBM’s Cognitive Computing Infrastructure and sophisticated machine learning algorithms Analytical data is used to identify correlations between different rehabilitation regimens with the goal of improving outcomes of neurol
Slide 12: Upper Body Products - Evidence Based and Clinically Proven
Upper Body Products - Evidence Based and Clinically Proven • Extensive pool of research supports the clinical efficacy of InMotion Robots • Over 1000 patients have been studied in clinical trials at prestigious academic and clinical sites using InMotion systems (formerly known as MIT Manus) • Over 8
Slide 13: Upper Extremity Clinical System - Evaluation
Upper Extremity Clinical System - Evaluation • InMotion EVAL™ • 4 tests; 9 measures of kinematic measures • Patient Evaluation System that calculates measures of motor control and movement recovery and are correlated to traditional assessment scales* 13 * Bosecker , C, et al., “Kinematic Robot - Bas
Slide 14: Healthcare Cost – SCI & Stroke
Healthcare Cost – SCI & Stroke Spinal Cord Injuries [1] • Length of initial hospitalization following injury in acute care units: 11 days • Average stay in - patient rehabilitation unit: 36 days • Average Lifetime Costs (3) : Stroke • In the US, heart attack and stroke costs are estimated at over $3
Slide 15: Sizing the Market
Sizing the Market • There are approximately 276,000 people living with SCI in the USA, with an estimated annual 12,500 new cases. (1) Across the G20 this translates to an estimated 4,000,000 existing SCI and 180,000 new cases annually. • Of the global, annual, 16,000,000 stroke cases, 5,000,000 peop
Slide 16: Competitive Landscape for ARKE
Competitive Landscape for ARKE Company & Device Selling Price Status Tech Points REWALK (RWLK: NASDAQ) - Rewalk Personal 6.0 System $ 69,500 in USA € 52,500 in EU - CE Marks and FDA cleared for personal and rehabilitation use - FDA De Novo created PHL category; a new classification paradigm for powe
Slide 17: Business Model
Business Model 17 In - Patient Rehab • Lease/Rental model • Monthly fee to the hospital/clinic for use of the product Out - Patient Rehab • Revenue share or Lease/Rental model • Percentage of the per session therapy to Bionik Home Use • Rental or direct product sale • ARKE revenue can be generated b
Slide 18: Path to Commercialization
Path to Commercialization 18 Market Canada European Union United States Regulating Authority Health Canada Medical Device Regulations (MDR) Notified Body Medical Device Directive (MDD) Food & Drug Administration 21 CFR Classification Class I Class II a Class II w/ special controls License Avenue Med
Slide 19: Reimbursement: Landmark Policy Granted Dec. 2015
Reimbursement: Landmark Policy Granted Dec. 2015 • Currently no universal coverage; however successful reimbursement on a case - by - case has been achieved • Etiology of injury impacts financing plan – e.g. vehicle accidents (automobile liability and Personal Injury Protection); workplace (workman’
Slide 20: RATULS Trial – Expected to Impact Reimbursement and Market Expansion
RATULS Trial – Expected to Impact Reimbursement and Market Expansion • Landmark study: Largest study ever conducted with robotics rehabilitation • Three arm randomised controlled trial designed to determine whether robot assisted training improves upper limb function post stroke using InMotion thera
Slide 21: Robust Intellectual Property
Robust Intellectual Property Area Of IP Status Filing Year Algorithms & Control Systems Filed US & International 2012 Sensory Technology Filed US & International 2012 Robotics Filed US & International 2012 Robotics Filed US & International 2012 Robotics Filed US & International 2012 Robotics US Prov
Slide 22: Growth Strategy Focused on Further Pipeline Expansion
University Networks Expanded and Focused Development Programs In - house R&D Licensing / Acquisitions Industry Partners MIT Technology Growth Strategy Focused on Further Pipeline Expansion • Leverage our in - depth research and development relationships within the space along with our relationship w
Slide 23: World Class Management Team
World Class Management Team 23 • Peter Bloch, CPA, CA – Chief Executive Officer • Over 25 years of executive management experience with proven track record of building public and private technology companies. Former CFO and joint Interim CEO of Sanofi Canada, CFO of Intellivax , Gennum TSX:GNM (n/k/
Slide 24: Board and Advisors Strengthens Capabilities
Board and Advisors Strengthens Capabilities 24 Advisors • Neville Hogan, Ph.D., M.S, M.E. • Sun Jae Professor of Mechanical Engineering, Professor of Brain and Cognitive Sciences, and Director of the Newman Laboratory for Biomechanics and Human Rehabilitation at MIT • Gary Henley • Significant medte
Slide 25: Financial Snapshot
Financial Snapshot - OTCQX: BNKL Stock Ticker Symbol OTCQX: BNKL Market Capitalization as of April 29, 2016 $98 M Shares Outstanding 1 96.2 M Warrants at exercise price of $1.40 16.4 M Warrants at exercise price of $0.80 1.49 M R ecent financings: February - July , 2015 $13.1 M Cash as of December 3
Slide 26: 2016 Expected Milestones Expected to Drive Value
2016 Expected Milestones Expected to Drive Value 26 • Complete integration of IMT • Appoint Chief Commercial Officer • Focus on revenue generation and market expansion • Advance development products through to commercialization • Further expand product portfolio through acquisitions/licensing • Stre
Slide 27: www.bioniklabs.com
www.bioniklabs.com OTCQX:BNKL Pioneering global medical device and robotics company focused on providing rehabilitation solutions to individuals with neurological disorders Corporate Presentation
Bionik Laboratories — Investor Presentation (May 2016) on 6ix